HOBOKEN, N.J.--(BUSINESS WIRE)--Castor, a leading provider of clinical trial technology to democratize clinical research, announced two executive appointments to accelerate the company’s growth and impact on the industry. Kimberly Tableman joins Castor as Chief Clinical Development Officer (CCDO) and Anna Wozniak as Chief Financial & Development Officer (CFDO).
Castor’s new CCDO, Kimberly Tableman, brings more than 23 years of experience in clinical development and technology. Over the past decade, she has focused on applying digital health technologies to reimagine the patient journey. She was most recently CEO at Medicine X, and co-founder at Rabble Health, where she led the development and beta launch of a patient engagement platform to serve oncology patients. Prior to Medicine X, Kimberly held senior roles at GlaxoSmithKline (GSK), including Head of Patient Engagement and Head of Digital Clinical Trials. She has also worked at Pfizer, and began her career in management consulting at Cap Gemini Ernst & Young.
“I am passionately committed to serving diverse patients through products that facilitate a positive research journey and increase accessibility to precision-medicine treatments,” said Tableman. “I am thrilled to be a part of the Castor team and to work alongside peers who are equally dedicated to making patient-centric trials a reality.”
Anna Wozniak, Castor’s new CFDO, brings more than 14 years of life sciences experience, building and scaling businesses through her focus on strategy, leadership, and driving execution. Anna was previously Executive Vice President Strategy and Development at BC Platforms, a personalized medicine company, driving growth post-Series A through Series C. Before joining BC Platforms, she held various finance and strategy roles at Syngenta.
“Castor’s technology-first approach to patient-centric research is primed for continued growth given the significant market need for digital transformation,” said Wozniak. “My experience scaling businesses and accelerating growth has led me to Castor - to deliver on the promise of enabling faster, smarter, clinical research.”
“Castor has grown tremendously in the past year, and with Anna and Kimberly - we add two strong, strategic leaders to help guide us during this phase of our growth,” said Derk Arts, M.D., Ph.D., CEO & Founder, Castor. “I am delighted to welcome Anna and Kimberly to Castor, both highly skilled professionals with decades of experience within these critical corporate operational areas to ensure we can continue to successfully help researchers conduct more effective clinical trials on a global scale, while improving the patient experience.”
Learn more about Castor’s expanding leadership team here. And, if you’re interested in joining a passionate and collaborative organization bringing clinical trials into the 21st century, Castor is hiring.
Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture.
Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide.
For more information, visit www.castoredc.com. Follow us on Twitter at @castor.